Patent application number | Description | Published |
20110200147 | HIGH-PERFORMANCE TONE DETECTION USING A DIGITAL SIGNAL PROCESSOR (DSP) HAVING MULTIPLE ARITHMETIC LOGIC UNITS (ALUS) - In one embodiment, a DSP having four arithmetic logic units (ALUs) and able to have two read/write operations per clock cycle performs silence detection and tone detection for data frames containing samples of an audio signal. The ALUs are used together in parallel to process the samples in the data frames received by the DSP. A received data frame is filtered by the silence detection so that substantially silent frames are dropped and non-silent frames are further processed. In the tone detection, a filtered data frame is processed, four samples at a time, to determine the power of the signal at a given frequency, where the power determination is used to determine whether a given tone (i.e., a signal at a given frequency) is present in the data frame. | 08-18-2011 |
20110231673 | CRYPTOGRAPHIC PROCESSING USING A PROCESSOR - In one embodiment, a cryptography processor compatible with the Advanced Encryption Standard (AES) for encrypting and decrypting has a memory storing each element of an AES State, normally 8-bit long, in a corresponding memory space that is at least 9 bits long. Using the larger memory spaces, the processor performs modified AES transformations on the State. A modified column-mixing transformation uses bit-shifting and XOR operations, thereby avoiding some multiplications and modulo reductions and resulting in some 9-bit State elements. A modified byte-substitution transformation uses a 512-element look-up table to accommodate 9-bit inputs. The modified byte-substitution transformation is combined with a modified row-shifting transformation. The memory has data registers each holding four State elements. A modified expanded key schedule is used in a modified round-key-adding transformation that is combined with the modified column-mixing transformation, wherein all four elements stored in a single data register are processed together in some operations. | 09-22-2011 |
20120082220 | INTRA-MODE PREDICTION FOR A VIDEO TRANSCODER - A video transcoder for converting an encoded input video bit-stream having one spatial resolution into an encoded output video bit-stream having a lower spatial resolution, wherein learned statistics of intra-mode transcoding are used to constrain the search of intra modes for the output video bit-stream. The statistics of intra-mode transcoding can be gathered, e.g., by applying brute-force downsizing to a training set of video frames and then analyzing the observed intra-mode transcoding patterns to determine a transition-probability matrix for use during normal operation of the transcoder. The transition-probability matrix enables the transcoder to select appropriate intra modes for the output video bit-stream without performing a corresponding exhaustive full search, which advantageously reduces the computational complexity and processor load compared to those of a comparably performing prior-art video transcoder. | 04-05-2012 |
20120106642 | Motion Estimation for a Video Transcoder - A video transcoder for converting an encoded input video bit-stream having one spatial resolution into an encoded output video bit-stream having a lower spatial resolution, wherein motion-vector dispersion observed at the higher spatial resolution is quantified and used to configure the motion-vector search at the lower spatial resolution. For example, for video-frame areas characterized by relatively low motion-vector dispersion values, the motion-vector search may be performed over a relatively small vector space and with the use of fewer search patterns and/or hierarchical search levels. These constraints enable the transcoder to find appropriate motion vectors for inter-prediction coding without having to perform an exhaustive motion-vector search for these video-frame areas, which advantageously reduces the computational complexity and processor load compared to those of a comparably performing prior-art video transcoder. | 05-03-2012 |
20120155655 | MUSIC DETECTION BASED ON PAUSE ANALYSIS - In one embodiment, a pause-based music detection (MD) module detects music by analyzing pauses in a received audio signal. The energy of each frame of the signal is compared to an energy threshold to determine whether the frame corresponds to background noise only (i.e., a pause) or sound such as speech or music. A window having a number of frames is analyzed to determine whether there is a pause within the window. If no pauses are detected in the window, then the current frame is presumed to correspond to music. If a pause is detected, then the current frame is presumed to correspond to speech. In another embodiment, the pause-based MD module output is applied to Boolean “OR” logic along with a tone-based MD module output to generate a final MD decision. The tone-based MD module detects music by analyzing tones in the signal using any suitable tone-based MD algorithm. | 06-21-2012 |
20120158401 | MUSIC DETECTION USING SPECTRAL PEAK ANALYSIS - In one embodiment, a music detection (MD) module accumulates sets of one or more frames and performs FFT processing on each set to recover a set of coefficients, each corresponding to a different frequency k. For each frame, the module identifies candidate musical tones by searching for peak values in the set of coefficients. If a coefficient corresponds to a peak, then a variable TONE[k] corresponding to the coefficient is set equal to one. Otherwise, the variable is set equal to zero. For each variable TONE[k] having a value of one, a corresponding accumulator A[k] is increased. Candidate musical tones that are short in duration are filtered out by comparing each accumulator A[k] to a minimum duration threshold. A determination is made as to whether or not music is present based on a number of candidate musical tones and a sum of candidate musical tone durations using a state machine. | 06-21-2012 |
20120166773 | HASH PROCESSING USING A PROCESSOR - In certain embodiments, a digital signal processor (DSP) has multiple arithmetic logic units and a register module. The DSP is adapted to generate a message digest H from a message M in accordance with the SHA-1 standard, where M includes N blocks M | 06-28-2012 |
20120201370 | TIME-DOMAIN ACOUSTIC ECHO CONTROL - In one embodiment, an acoustic echo control (AEC) module receives an outgoing signal and an incoming signal, which, at various times, contains acoustic echo corresponding to the outgoing signal. The AEC module has a delay estimation block that estimates, in the time domain, the echo delay using an adaptive filtering technique. This delay estimation is used to align samples of the incoming signal having acoustic echo with the corresponding samples of the outgoing signal from which the acoustic echo originated. The AEC module determines whether or not samples of the incoming signal contain acoustic echo based on the aligned outgoing signal, and the determinations are applied to a hangover counter. The AEC module then suppresses acoustic echo in the incoming signal and adds comfort noise to the incoming signal. The amount of echo suppression performed is gradually increased or decreased based on comparisons of the counter to a hangover threshold. | 08-09-2012 |
20120224684 | SOFT ATTENUATION OF HIGH-POWER SIGNALS - In one embodiment, a high-level compensation (HLC) module receives samples of an input signal and determines whether a magnitude of each sample, represented in a linear domain, is relatively low or relatively high by comparing the magnitude to a threshold. If a sample is less than or equal to the threshold, then it is considered to have a relatively low magnitude and the sample is not attenuated. If a sample is greater than the threshold, then it is considered to have a relatively high magnitude and the HLC module attenuates the sample according to a “soft” non-linear function. The “soft” non-linear function is characterized by at least two of the following characteristics: the non-linear function (i) increases monotonically, (ii) forms a convex upwards curve, (iii) has a first derivative at the threshold equal to one, and (iv) has a first derivative at a maximum possible magnitude value equal to zero. | 09-06-2012 |
Patent application number | Description | Published |
20080228051 | ANALYTE MEASURING DEVICE - An implantable analyte-measuring device including a membrane adapted to promote vascularization and/or interfere with barrier cell layer formation. The membrane includes any combination of materials, architecture, and bioactive agents that facilitate analyte transport to provide long-term in vivo performance of the implantable analyte-measuring device. | 09-18-2008 |
20080228054 | ANALYTE MEASURING DEVICE - An implantable analyte-measuring device including a membrane adapted to promote vascularization and/or interfere with barrier cell layer formation. The membrane includes any combination of materials, architecture, and bioactive agents that facilitate analyte transport to provide long-term in vivo performance of the implantable analyte-measuring device. | 09-18-2008 |
20090299276 | INTEGRATED DELIVERY DEVICE FOR CONTINUOUS GLUCOSE SENSOR - Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction. | 12-03-2009 |
20100100116 | INTRAGASTRIC VOLUME-OCCUPYING DEVICE AND METHOD FOR FABRICATING SAME - Intragastric volume-occupying devices and methods for treating obesity are provided. The devices, which are inflated by carbon dioxide, include an aluminum or silicon oxide barrier layer providing carbon dioxide retention and an alkylene vinyl alcohol polymer layer providing structural integrity in vivo. | 04-22-2010 |
20100100117 | INTRAGASTRIC DEVICE - An implant configured for ingestion by a patient. After the implant has been swallowed by the patient and is disposed within the target location, e.g. the patient's stomach, an inflation subcomponent causes the implant to expand from a compact delivery state to an expanded, volume-occupying, deployed state. In the deployed state the implant creates a sensation of satiety in the patient stomach and thereby aids in limiting food intake and obesity. After a predetermined time a deflation subcomponent is actuated and the implant reduces in size so as to allow it to pass through the remainder of the patient's digestive track. The device may further incorporate tracking and visualization subcomponents, as well as pharmaceutical delivery subcomponents. | 04-22-2010 |
20100137897 | INTRAGASTRIC DEVICE - An implant configured for ingestion by a patient. After the implant has been swallowed by the patient and is disposed within the target location, e.g. the patient's stomach, an inflation subcomponent causes the implant to expand from a compact delivery state to an expanded, volume-occupying, deployed state. In the deployed state the implant creates a sensation of satiety in the patient stomach and thereby aids in limiting food intake and obesity. After a predetermined time a deflation subcomponent is actuated and the implant reduces in size so as to allow it to pass through the remainder of the patient's digestive track. The device may further incorporate tracking and visualization subcomponents, as well as pharmaceutical delivery subcomponents. | 06-03-2010 |
20110270158 | INTEGRATED DELIVERY DEVICE FOR CONTINUOUS GLUCOSE SENSOR - Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction. | 11-03-2011 |
20120186581 | INTEGRATED DELIVERY DEVICE FOR CONTINUOUS GLUCOSE SENSOR - Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction. | 07-26-2012 |
20120190953 | INTEGRATED DELIVERY DEVICE FOR CONTINUOUS GLUCOSE SENSOR - Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction. | 07-26-2012 |
20120191063 | INTEGRATED DELIVERY DEVICE FOR CONTINUOUS GLUCOSE SENSOR - Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction. | 07-26-2012 |
20120191123 | INTRAGASTRIC DEVICE - Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided. | 07-26-2012 |
20120191124 | INTRAGASTRIC DEVICE - Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided. | 07-26-2012 |
20120215201 | INTEGRATED DELIVERY DEVICE FOR CONTINUOUS GLUCOSE SENSOR - Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction. | 08-23-2012 |
20120220979 | INTEGRATED DELIVERY DEVICE FOR CONTINUOUS GLUCOSE SENSOR - Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction. | 08-30-2012 |
20120232576 | INTRAGASTRIC DEVICE - Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided. | 09-13-2012 |
20120238852 | INTEGRATED DELIVERY DEVICE FOR CONTINUOUS GLUCOSE SENSOR - Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction. | 09-20-2012 |
20120265234 | INTRAGASTRIC DEVICE - An implant configured for ingestion by a patient. After the implant has been swallowed by the patient and is disposed within the target location, e.g. the patient's stomach, an inflation subcomponent causes the implant to expand from a compact delivery state to an expanded, volume-occupying, deployed state. In the deployed state the implant creates a sensation of satiety in the patient stomach and thereby aids in limiting food intake and obesity. After a predetermined time a deflation subcomponent is actuated and the implant reduces in size so as to allow it to pass through the remainder of the patient's digestive track. The device may further incorporate tracking and visualization subcomponents, as well as pharmaceutical delivery subcomponents. | 10-18-2012 |
20120296311 | INTEGRATED DELIVERY DEVICE FOR CONTINUOUS GLUCOSE SENSOR - Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction. | 11-22-2012 |
20130012980 | INTRAGASTRIC DEVICE - Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided. | 01-10-2013 |
20130131478 | ANALYTE SENSORS HAVING A SIGNAL-TO-NOISE RATIO SUBSTANTIALLY UNAFFECTED BY NON-CONSTANT NOISE - Systems and methods of use involving sensors having a signal-to-noise ratio that is substantially unaffected by non-constant noise are provided for continuous analyte measurement in a host. In some embodiments, a continuous analyte measurement system is configured to be wholly, transcutaneously, intravascularly or extracorporeally implanted. | 05-23-2013 |
20130289604 | INTRAGASTRIC DEVICE - Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided. | 10-31-2013 |
20140128703 | ANALYTE SENSORS HAVING A SIGNAL-TO-NOISE RATIO SUBSTANTIALLY UNAFFECTED BY NON-CONSTANT NOISE - Systems and methods of use involving sensors having a signal-to-noise ratio that is substantially unaffected by non-constant noise are provided for continuous analyte measurement in a host. In some embodiments, a continuous analyte measurement system is configured to be wholly, transcutaneously, intravascularly or extracorporeally implanted. | 05-08-2014 |
20140128704 | ANALYTE SENSORS HAVING A SIGNAL-TO-NOISE RATIO SUBSTANTIALLY UNAFFECTED BY NON-CONSTANT NOISE - Systems and methods of use involving sensors having a signal-to-noise ratio that is substantially unaffected by non-constant noise are provided for continuous analyte measurement in a host. In some embodiments, a continuous analyte measurement system is configured to be wholly, transcutaneously, intravascularly or extracorporeally implanted. | 05-08-2014 |
20140275900 | BIOINTERFACE MEMBRANES INCORPORATING BIOACTIVE AGENTS - A biointerface membrane for an implantable device including a nonresorbable solid portion with a plurality of interconnected cavities therein adapted to support tissue ingrowth in vivo, and a bioactive agent incorporated into the biointerface membrane and adapted to modify the tissue response is provided. The bioactive agents can be chosen to induce vascularization and/or prevent barrier cell layer formation in vivo, and are advantageous when used with implantable devices wherein solutes are transported across the device-tissue interface. | 09-18-2014 |
Patent application number | Description | Published |
20090297471 | Methods For Autologous Stem Cell Transplantation - Materials and methods for obtaining populations of lymphocytes and administering the population of lymphocytes to a subject are disclosed herein. In particular, disclosed herein are materials and methods for obtaining lymphocyte populations that contain at least about 0.5×10 | 12-03-2009 |
20100047234 | TREATING SKIN CANCER - This document provides methods and materials related to treating skin cancer. For example, methods and materials relating to the use of a taxane compound, an alkylating agent, and an anti-VEGF polypeptide antibody to treat skin cancer are provided. | 02-25-2010 |
20110150902 | TREATING CANCER - This document relates to methods and materials involved in treating cancer (e.g., melanoma). For example, methods and materials involved in using an anti-chronic inflammation treatment (e.g., chemotherapy) in combination with a cancer treatment agent (e.g., a cancer vaccine) to treat cancer are provided. | 06-23-2011 |
20110190219 | TREATING CANCER WITH GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR - Methods for treating cancer (e.g., metastatic cancer to the lung or chronic lymphocytic leukemia) in patients are described that include administrating an aerosolized granulocyte macrophage colony stimulating factor to the patients. Methods for stimulating an immune response in patients also are described. | 08-04-2011 |
20120303284 | DETERMINATION OF TIMING OF CHEMOTHERAPY DELIVERY - A system and method for determination of one or more favorable time(s) for chemotherapy or other pharmacological treatment delivery analyze time-dependent fluctuations of at least one biological variable measured in blood samples obtained from clinical patients and determine one or more favorable times for the pharmacological treatment of the patient. In some examples, the biological variables are immune variables. | 11-29-2012 |
20140056909 | TREATING CANCER - This document relates to methods and materials involved in treating cancer (e.g., melanoma). For example, methods and materials involved in using an anti-chronic inflammation treatment (e.g., chemotherapy) in combination with a cancer treatment agent (e.g., a cancer vaccine) to treat cancer are provided. | 02-27-2014 |
20140178486 | CANCER TREATEMENTS - This document provides methods and materials related to treating cancer (e.g., skin cancer). For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., Abraxane®/anti-VEGF polypeptide antibody complexes) to treat cancer (e.g., skin cancer) are provided. | 06-26-2014 |
20140271674 | METHODS AND MATERIALS FOR TREATING CANCER - This document provides methods and materials involved in treating cancer. For example, methods and materials for identifying a mammal as having an elevated level of PD-1 | 09-18-2014 |
20140302017 | TREATING SKIN CANCER - This document provides methods and materials related to treating skin cancer. For example, methods and materials relating to the use of a taxane compound, an alkylating agent, and an anti-VEGF polypeptide antibody to treat skin cancer are provided. | 10-09-2014 |
20140369955 | METHODS FOR AUTOLOGOUS STEM CELL TRANSPLANTATION - Materials and methods for obtaining populations of lymphocytes and administering the population of lymphocytes to a subject are disclosed herein. In particular, disclosed herein are materials and methods for obtaining lymphocyte populations that contain at least about 0.5×10 | 12-18-2014 |